KIDNEY DISEASE

US$3.5BN kidney deal puts DXB’s current valuation in perspective

Next Investors Jul 04, 2023

Last month, a big pharma company swooped on two treatments for a rare kidney disease in a US$3.5BN deal. This $3.5BN deal sets a benchmark price by big pharma on later stage assets treating rare kidney diseases. It also highlights the M&A appetite for kidney drug development.

Potential new use of DXB’s drug in US$2.5 Billion market

Next Investors Jun 08, 2022

Yesterday our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), announced an agreement with the Australian Centre for Accelerating Diabetes Innovation to commence a clinical trial on Diabetic Kidney Disease expected Q4 2022.

DXB Actively Recruiting Patients Across the Globe, First Dosing Soon

Next Investors Apr 27, 2022

DXB is a long-term position for us, and despite its share price performance over recent weeks, we’re quietly satisfied with its progress to date - especially on the FSGS front.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Finfeed Feb 28, 2022

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Next Investors Feb 28, 2022

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

Earlier than Expected - DXB Gets First Regulatory Approval in Europe.

Next Investors Feb 01, 2022

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

DXB kidney disease treatment Phase III trial officially begins

Finfeed Oct 21, 2021

Today DXB announced that the ethics approval was granted for its Phase III clinical trial on kidney disease FSGS, marking the “official start” of the trial.

DXB kicks off Phase 3 clinical trials - Ethics approval lodged

Finfeed Aug 26, 2021

Yesterday Dimerix (ASX:DXB) announced its first “ethics submission” in Australia. Once approved, the patient recruitment process can begin for the Phase 3 trials. We will provide our commentary at every step in the process.

The first investment in our new early stage, ASX listed biotech portfolio

Finfeed Aug 16, 2021

Everything that you need to know about investing in Dimerix (ASX:DXB). A comprehensive summary of 9 reasons why we have invested in DXB. Upcoming projects, and milestones.